**Trader consensus heavily favors no hantavirus vaccine approval or availability by the end of 2026, driven by the early stage of all candidates despite recent research momentum.** Most efforts remain in preclinical testing or Phase 1 trials, with mRNA platforms from Moderna-Korea University and UTMB showing protection in animal models against strains like Andes virus but lacking human efficacy data. Inactivated vaccines exist for select Old World hantaviruses in parts of Asia, yet none target dominant New World strains or meet Western regulatory standards, and WHO recognizes no licensed options. Vaccine development for rare, rodent-borne pathogens typically requires years of phased trials, manufacturing scale-up, and large-scale safety studies, with no emergency-use pathway or major funding surge currently in place. A major outbreak could accelerate timelines, but model projections and trial registries indicate this remains improbable before 2027.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেডHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
5% সম্ভাবনা
$135,595 Vol.
$135,595 Vol.
Dec 31, 2026
5% সম্ভাবনা
$135,595 Vol.
$135,595 Vol.
Dec 31, 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.**Trader consensus heavily favors no hantavirus vaccine approval or availability by the end of 2026, driven by the early stage of all candidates despite recent research momentum.** Most efforts remain in preclinical testing or Phase 1 trials, with mRNA platforms from Moderna-Korea University and UTMB showing protection in animal models against strains like Andes virus but lacking human efficacy data. Inactivated vaccines exist for select Old World hantaviruses in parts of Asia, yet none target dominant New World strains or meet Western regulatory standards, and WHO recognizes no licensed options. Vaccine development for rare, rodent-borne pathogens typically requires years of phased trials, manufacturing scale-up, and large-scale safety studies, with no emergency-use pathway or major funding surge currently in place. A major outbreak could accelerate timelines, but model projections and trial registries indicate this remains improbable before 2027.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
মার্কেট ওপেন হয়েছে: May 4, 2026, 10:39 AM ET
ভলিউম
$135,595শেষ তারিখ
Jan 1, 2027মার্কেট ওপেন হয়েছে
May 4, 2026, 10:39 AM ETরেজলভার
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.**Trader consensus heavily favors no hantavirus vaccine approval or availability by the end of 2026, driven by the early stage of all candidates despite recent research momentum.** Most efforts remain in preclinical testing or Phase 1 trials, with mRNA platforms from Moderna-Korea University and UTMB showing protection in animal models against strains like Andes virus but lacking human efficacy data. Inactivated vaccines exist for select Old World hantaviruses in parts of Asia, yet none target dominant New World strains or meet Western regulatory standards, and WHO recognizes no licensed options. Vaccine development for rare, rodent-borne pathogens typically requires years of phased trials, manufacturing scale-up, and large-scale safety studies, with no emergency-use pathway or major funding surge currently in place. A major outbreak could accelerate timelines, but model projections and trial registries indicate this remains improbable before 2027.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
ভলিউম
$135,595শেষ তারিখ
Jan 1, 2027মার্কেট ওপেন হয়েছে
May 4, 2026, 10:39 AM ETরেজলভার
0x65070BE91...**Trader consensus heavily favors no hantavirus vaccine approval or availability by the end of 2026, driven by the early stage of all candidates despite recent research momentum.** Most efforts remain in preclinical testing or Phase 1 trials, with mRNA platforms from Moderna-Korea University and UTMB showing protection in animal models against strains like Andes virus but lacking human efficacy data. Inactivated vaccines exist for select Old World hantaviruses in parts of Asia, yet none target dominant New World strains or meet Western regulatory standards, and WHO recognizes no licensed options. Vaccine development for rare, rodent-borne pathogens typically requires years of phased trials, manufacturing scale-up, and large-scale safety studies, with no emergency-use pathway or major funding surge currently in place. A major outbreak could accelerate timelines, but model projections and trial registries indicate this remains improbable before 2027.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেড
বাহ্যিক লিংক থেকে সাবধান।
বাহ্যিক লিংক থেকে সাবধান।
সচরাচর জিজ্ঞাসা